Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18237246rdf:typepubmed:Citationlld:pubmed
pubmed-article:18237246lifeskim:mentionsumls-concept:C0262950lld:lifeskim
pubmed-article:18237246lifeskim:mentionsumls-concept:C0019829lld:lifeskim
pubmed-article:18237246lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:18237246lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:18237246pubmed:issue2lld:pubmed
pubmed-article:18237246pubmed:dateCreated2008-2-1lld:pubmed
pubmed-article:18237246pubmed:abstractTextThe purpose of the study is to determine incidence and prognostic impact of osseous Hodgkin lymphoma (HL). Between 1997 and 2004, 198 patients with HL were treated at our institution. Advanced stages and nodular sclerosis histology prevailed. All patients were treated according to protocols of the German Hodgkin Study Group (GHSG). After minimum follow-up of 24 months, we retrospectively analyzed the incidence of osseous HL, treatment response and parameters of survival. We recorded 14 cases of osseous HL (7 %), always with concurrent nodal disease. Axial skeleton was most frequently involved. Eleven patients (78,5 %) achieved complete remission and three (21,5 %) progressed primarily. The patients with osseous HL had significantly lower 2-year freedom from treatment failure than the patients without bone involvement (71,4 and 92,7 %, respectively, p=0,004), with no significant difference in 2-year overall survival (85,7 and 95 %, respectively, p=0,14). On multivariate analysis, advanced stage was the only independent adverse prognostic factor. In conclusion, bone involvement is a relatively common finding in HL and is not an independent adverse prognostic factor.lld:pubmed
pubmed-article:18237246pubmed:languageenglld:pubmed
pubmed-article:18237246pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18237246pubmed:citationSubsetIMlld:pubmed
pubmed-article:18237246pubmed:statusMEDLINElld:pubmed
pubmed-article:18237246pubmed:issn0028-2685lld:pubmed
pubmed-article:18237246pubmed:authorpubmed-author:KozarSSlld:pubmed
pubmed-article:18237246pubmed:authorpubmed-author:FeltsMMlld:pubmed
pubmed-article:18237246pubmed:authorpubmed-author:MarkovaJJlld:pubmed
pubmed-article:18237246pubmed:authorpubmed-author:MocikovaHHlld:pubmed
pubmed-article:18237246pubmed:authorpubmed-author:DedeckovaKKlld:pubmed
pubmed-article:18237246pubmed:issnTypePrintlld:pubmed
pubmed-article:18237246pubmed:volume55lld:pubmed
pubmed-article:18237246pubmed:ownerNLMlld:pubmed
pubmed-article:18237246pubmed:authorsCompleteYlld:pubmed
pubmed-article:18237246pubmed:pagination96-100lld:pubmed
pubmed-article:18237246pubmed:meshHeadingpubmed-meshheading:18237246...lld:pubmed
pubmed-article:18237246pubmed:meshHeadingpubmed-meshheading:18237246...lld:pubmed
pubmed-article:18237246pubmed:meshHeadingpubmed-meshheading:18237246...lld:pubmed
pubmed-article:18237246pubmed:meshHeadingpubmed-meshheading:18237246...lld:pubmed
pubmed-article:18237246pubmed:meshHeadingpubmed-meshheading:18237246...lld:pubmed
pubmed-article:18237246pubmed:meshHeadingpubmed-meshheading:18237246...lld:pubmed
pubmed-article:18237246pubmed:meshHeadingpubmed-meshheading:18237246...lld:pubmed
pubmed-article:18237246pubmed:meshHeadingpubmed-meshheading:18237246...lld:pubmed
pubmed-article:18237246pubmed:meshHeadingpubmed-meshheading:18237246...lld:pubmed
pubmed-article:18237246pubmed:meshHeadingpubmed-meshheading:18237246...lld:pubmed
pubmed-article:18237246pubmed:year2008lld:pubmed
pubmed-article:18237246pubmed:articleTitlePrognostic impact of bone involvement in Hodgkin lymphoma.lld:pubmed
pubmed-article:18237246pubmed:affiliationDepartment of Oncology, University Hospital Ostrava, Czech Republic. david.feltl@fnspo.czlld:pubmed
pubmed-article:18237246pubmed:publicationTypeJournal Articlelld:pubmed